Key Points
- Centessa insider Karen Anderson sold 64,768 shares on March 16 at an average price of $28.21 for about $1.83 million, leaving her with 62,085 shares and a reported 51.06% reduction in ownership.
- Analysts are largely positive, with a MarketBeat consensus rating of "Buy" and a consensus target price of $39.80 after multiple firms initiated coverage or raised price objectives.
- Institutional investors own 82.01% of the stock, and several large funds (Avoro, Adage, Farallon, Siren) materially increased their stakes in the latest quarter.
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) insider Karen Anderson sold 10,043 shares of the firm's stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $28.10, for a total transaction of $282,208.30. Following the completion of the sale, the insider directly owned 62,085 shares of the company's stock, valued at approximately $1,744,588.50. This represents a 13.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Centessa Pharmaceuticals Price Performance
Shares of NASDAQ CNTA opened at $28.71 on Thursday. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $9.60 and a 1 year high of $30.58. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57. The company's 50-day moving average is $25.05 and its 200 day moving average is $24.54. The stock has a market capitalization of $4.19 billion, a P/E ratio of -15.69 and a beta of 1.55.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on CNTA. Oppenheimer increased their target price on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an "outperform" rating in a research report on Wednesday, December 10th. B. Riley Financial upped their price target on Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a "buy" rating in a research note on Monday, December 1st. TD Cowen reiterated a "buy" rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 21st. Finally, Truist Financial boosted their target price on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a "buy" rating in a report on Thursday, January 29th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $39.80.
Read Our Latest Research Report on CNTA
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC boosted its holdings in Centessa Pharmaceuticals by 52.9% in the first quarter. Millennium Management LLC now owns 609,188 shares of the company's stock worth $8,760,000 after acquiring an additional 210,737 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Centessa Pharmaceuticals during the first quarter valued at $2,176,000. Campbell & CO Investment Adviser LLC bought a new position in shares of Centessa Pharmaceuticals during the second quarter valued at $218,000. Geode Capital Management LLC raised its position in shares of Centessa Pharmaceuticals by 44.7% in the 2nd quarter. Geode Capital Management LLC now owns 87,435 shares of the company's stock worth $1,149,000 after purchasing an additional 26,994 shares during the last quarter. Finally, Ensign Peak Advisors Inc boosted its stake in Centessa Pharmaceuticals by 27.8% in the 2nd quarter. Ensign Peak Advisors Inc now owns 559,744 shares of the company's stock worth $7,355,000 after purchasing an additional 121,611 shares in the last quarter. Institutional investors own 82.01% of the company's stock.
About Centessa Pharmaceuticals
(
Get Free Report)
Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.
Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
